Table 1.
Baseline characteristics compared between cholangiocarcinoma and control groups
| Control n = 3174 | CCA n = 3174 | ||||
|---|---|---|---|---|---|
| n | % | n | % | P value | |
| Age group (years) | 0.001 | ||||
| ≤64 | 1183 | 37.3 | 1289 | 40.6 | |
| 65–74 | 880 | 27.7 | 933 | 29.4 | |
| ≥75 | 1111 | 35.0 | 952 | 30.0 | |
| Mean (SD) (years)* | 68.5 | 13.2 | 67.4 | 12.3 | 0.001 |
| Gender | 0.78 | ||||
| Female | 1548 | 48.8 | 1559 | 49.1 | |
| Male | 1626 | 51.2 | 1615 | 50.9 | |
| Medications | |||||
| Statin | 840 | 26.5 | 720 | 22.7 | <0.001 |
| Aspirin | 1515 | 47.7 | 1534 | 48.3 | 0.63 |
| Metformin | 714 | 22.5 | 732 | 23.1 | 0.59 |
| CCI score† | 0.15 | ||||
| 0 | 1510 | 47.6 | 1596 | 50.3 | |
| 1 | 967 | 30.5 | 898 | 28.3 | |
| 2 | 350 | 11.0 | 350 | 11.0 | |
| 3 or more | 347 | 10.9 | 330 | 10.4 | |
| Baseline co-morbidities | |||||
| Diabetes | 767 | 24.2 | 772 | 24.3 | 0.88 |
| Cirrhosis | 1826 | 57.5 | 1818 | 57.3 | 0.84 |
| Chronic pancreatitis† | 35 | 1.10 | 34 | 1.07 | 0.90 |
| Hepatitis B infection | 569 | 17.9 | 537 | 16.9 | 0.29 |
| Hepatitis C infection | 320 | 10.1 | 323 | 10.2 | 0.90 |
| Gastric disease | 2152 | 67.8 | 2124 | 66.9 | 0.45 |
| Haemochromatosis† | 1 | 0.03 | 1 | 0.03 | 0.99 |
| Inflammatory bowel disease | 94 | 2.96 | 94 | 2.96 | 0.99 |
| Biliary tract disease | 1267 | 39.9 | 1303 | 41.1 | 0.36 |
| Stroke | 371 | 11.7 | 346 | 10.9 | 0.32 |
| CAD | 999 | 31.5 | 1021 | 32.2 | 0.55 |
| COPD | 686 | 21.6 | 713 | 22.5 | 0.41 |
| Alcohol-related illness | 263 | 8.29 | 271 | 8.54 | 0.72 |
Chi-square test,
*
t-test and
†
Fisher-exact test comparing subjects with and without CCA.
Data are presented as the number of subjects in each group, with percentages given in parentheses.
CCA cholangiocarcinoma
‡
CCI score, Charlson comorbidity index score.